Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel treatments for serious bacterial infections. Headquartered in Cambridge, Massachusetts, the company aims to address the growing global threat of antibiotic resistance by creating therapies that target multidrug-resistant pathogens. Spero’s research platform leverages proprietary chemistry and deep biological insights to expand options in anti-infective care, with an emphasis on oral and intravenous formulations.
The company’s lead product candidate is tebipenem HBr (SPR994), an oral carbapenem antibiotic designed for the treatment of complicated urinary tract infections and pyelonephritis caused by multidrug-resistant Gram-negative bacteria. In parallel, Spero is advancing SPR206, an intravenous polymyxin derivative intended to treat serious hospital-acquired and ventilator-associated bacterial pneumonia. These candidates exemplify the company’s strategy to develop therapies that deliver strong antibacterial activity while minimizing toxicity and adverse effects.
Since its founding in 2014, Spero Therapeutics has built strategic partnerships to bolster its development and commercialization efforts, including collaborations with global pharmaceutical firms and research institutions. The company’s operations extend beyond the United States, encompassing clinical trial sites and regulatory interactions in North America, Europe, and Asia. By engaging with international health authorities and academic experts, Spero seeks to streamline the path to approval for critical new antibiotics.
Under the leadership of President and Chief Executive Officer Ankit Mahadevia, Spero has assembled a team of experienced biopharmaceutical professionals with expertise in infectious disease research, clinical development, and regulatory affairs. With a focus on scientific rigor and patient-centered innovation, the company continues to advance its pipeline toward regulatory milestones and potential commercialization, aiming to bring much-needed options to physicians and patients facing resistant infections.
AI Generated. May Contain Errors.
